About Sai Life Sciences Limited
Data last updated: 27 December 2025
Sai Life Sciences Limited is a public limited company based in Hyderabad, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 25 January 1999, the company has been in operation for over 27 years.
Registered with ROC Hyderabad under CIN L24110TG1999PLC030970. Listed.
Capital: an authorised share capital of ₹25 Cr and a paid-up capital of ₹21.12 Cr. Formerly known as Sai Dru Syn Laboratories Limited and Sai Advantium Pharma Limited Definitions & Interpretation. It is led by directors including Krishnamraju Kanumuri and Sivaramakrishnan Chittor.
Last AGM: 11 September 2025. Financial statements filed for year ended 31 March 2025. Office: 7 Ikp Knowledge Park, Hyderabad, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,731.35 Cr, a growth of 16% compared to the previous year.
The company has a workforce of approximately 2,995 employees as per the latest available data.
The company is associated with 1 brand - Sai Life Sciences. As per MCA filings, the company has open charges of ₹912.36 Cr and satisfied charges of ₹1,590.09 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sailife.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressPlot No. Ds – 7 Ikp Knowledge Park Turkapally (V) Shameerpet Mandal Medchal – Malkajgiri Di, St, Hyderabad, Telangana, India – 500078
-
IndustryPharma, API Manufacturers, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Sai Life Sciences Limited
Sai Life Sciences Limited has undergone 4 name changes throughout its history. The current legal name is Sai Life Sciences Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Sai Life Sciences Limited | Current |
| Sai Dru Syn Laboratories Limited | Previous |
| Sai Advantium Pharma Limited Definitions & Interpretation | Previous |
| Sai Life Sciences Limited Definitions & Interpretation | Previous |
| Sai Advantium Pharma Limited | Previous |
CIN History of Sai Life Sciences Limited
Sai Life Sciences Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24110TG1999PLC030970, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1999PLC030970 | Current |
| U24110TG1999PLC030970 | Previous |
| U24110AP1999PLC030970 | Previous |
Associated Brands with Sai Life Sciences Limited
Sai Life Sciences Limited operates one associated brand: Sai Life Sciences. These brands represent Sai Life Sciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Complex small molecules are discovered, developed, and manufactured for pharmaceuticals. | sailife.com |
Competitors & Alternatives of Sai Life Sciences Limited
Brands and companies operating in the same space as Sai Life Sciences Limited include Acies Bio, Liverpool ChiroChem, IRBM and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Acies Bio
|
Provider of drug discovery and development services to pharmaceutical, biotech, and food industries | Ljubljana, Slovenia, Slovenia | 2006 |
Liverpool ChiroChem
|
Small organic molecules are supplied for biotech and pharmaceutical R&D. | Liverpool, United Kingdom, United Kingdom | 2014 |
IRBM
|
Integrated drug discovery and preclinical development services are provided. | Pomezia, Italy, Italy | 2010 |
New Iridium
|
Phenoxazine and dihydrophenazine are manufactured by New Iridium. | Boulder, United States, United States | 2016 |
NFIL
|
Fluorinated compounds are synthesized and manufactured customly for various industries. | Mumbai, India, India | 1967 |
Personal Chemistry
|
Coherent Synthesis is developed for medicinal and combinatorial chemistry applications. | Uppsala, Sweden, Sweden | 1998 |
Automera
|
Autophagy-driven degradation is pioneered through computational chemistry and AI. | Singapore, Singapore, Singapore | 2022 |
SpiroChem
|
Swiss fine chemicals company providing API, Intermediates and custom synthesis services for the pharma and biotech industry | Zurich, Switzerland, Switzerland | 2011 |
Business Activity of Sai Life Sciences Limited
Sai Life Sciences Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Auditor Details of Sai Life Sciences Limited
Sai Life Sciences Limited is audited by Deloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Sai Life Sciences Limited
Sai Life Sciences Limited is currently managed by 6 directors, with 28 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Krishnamraju Kanumuri | Managing Director | 01 Oct 2010 | 15 Years 9 Months | Current |
|
Sivaramakrishnan Chittor
Also directs:
Sai Life Sciences Limited
|
Whole-Time Director | 28 Apr 2025 | 1 Years 2 Months | Current |
|
Ranga Raju Kanumuri
Also directs:
Jrv Properties Llp, Sai Life Sciences Limited, Sai Quest Syn Private Limited and 3 more
|
Whole-Time Director | 25 Jan 1999 | 27 Years 5 Months | Current |
| Suchita Sharma | Director | 10 Jun 2024 | 2 Years 0 Months | Current |
|
Ramesh Ganesh Iyer
Also directs:
Sai Life Sciences Limited, Nocil Limited, Mahindra First Choice Wheels Limited and 3 more
|
Director | 21 May 2024 | 2 Years 1 Months | Current |
|
Dinesh V Patel
Also directs:
Sai Life Sciences Limited
|
Director | 24 Mar 2025 | 1 Years 3 Months | Current |
Financials of Sai Life Sciences Limited FY 2026 filings available
Sai Life Sciences Limited reported revenue of ₹2,192.49 Cr (up 29.38% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹2,192.49 Cr | ₹1,694.57 Cr |
| Other Income | ₹49.13 Cr | ₹36.78 Cr |
| Total Income | ₹2,241.62 Cr | ₹1,731.35 Cr |
| Cost of Materials Consumed | ₹578.12 Cr | ₹460.8 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 |
| Changes in Inventories | -₹7.22 Cr | ₹4.97 Cr |
| Employee Benefit Expense | ₹683.06 Cr | ₹549.12 Cr |
| Finance Costs | ₹39.24 Cr | ₹76.16 Cr |
| Depreciation & Amortisation | ₹166.86 Cr | ₹138.57 Cr |
| Other Expenses | ₹307.39 Cr | ₹274.03 Cr |
| Total Expenses | ₹1,767.43 Cr | ₹1,503.65 Cr |
| Profit Before Exceptional Items & Tax | ₹474.19 Cr | ₹227.7 Cr |
| Exceptional Items | -₹8 Cr | ₹0 |
| Profit Before Tax | ₹466.19 Cr | ₹227.7 Cr |
| Total Tax Expense | ₹117.28 Cr | ₹57.57 Cr |
| Net Profit | ₹348.91 Cr | ₹170.13 Cr |
| Other Comprehensive Income | -₹20.82 Cr | ₹1.19 Cr |
| Total Comprehensive Income | ₹328.09 Cr | ₹171.32 Cr |
| EBITDA (computed) | ₹680.29 Cr | ₹442.44 Cr |
| Basic EPS | ₹16.63 | ₹8.83 |
| Diluted EPS | ₹16.43 | ₹8.61 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹3,626.14 Cr | ₹3,159.98 Cr |
| Non-current Assets | ₹2,215.61 Cr | ₹1,655.46 Cr |
| Current Assets | ₹1,410.53 Cr | ₹1,504.51 Cr |
| Property, Plant & Equipment | ₹1,808.72 Cr | ₹1,477.36 Cr |
| Inventories | ₹150.97 Cr | ₹118.87 Cr |
| Trade Receivables | ₹373.62 Cr | ₹354.78 Cr |
| Cash & Equivalents | ₹81.91 Cr | ₹91.12 Cr |
| Equity (Net Worth) | ₹2,483.69 Cr | ₹2,128.35 Cr |
| Equity Share Capital | ₹21.18 Cr | ₹20.84 Cr |
| Borrowings (Non-current) | ₹20.5 Cr | ₹0 |
| Borrowings (Current) | ₹74.62 Cr | ₹128.64 Cr |
| Total Debt (computed) | ₹95.13 Cr | ₹128.64 Cr |
| Current Liabilities | ₹833.68 Cr | ₹732.49 Cr |
| Total Liabilities | ₹1,142.45 Cr | ₹1,031.62 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹509.13 Cr | ₹314.05 Cr |
| Investing Cash Flow | -₹395.41 Cr | -₹536.67 Cr |
| Financing Cash Flow | -₹123.68 Cr | ₹301.43 Cr |
| Capital Expenditure | ₹592.96 Cr | ₹369.28 Cr |
| Free Cash Flow (computed) | -₹83.83 Cr | -₹55.24 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | -₹9.14 Cr | ₹79.08 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹602.14 Cr | ₹556.46 Cr | ₹537.47 Cr | ₹496.42 Cr | ₹579.51 Cr | ₹439.78 Cr |
| Other Income | ₹15.52 Cr | ₹8.38 Cr | ₹15.33 Cr | ₹9.9 Cr | ₹9.6 Cr | ₹9.12 Cr |
| Total Income | ₹617.66 Cr | ₹564.84 Cr | ₹552.8 Cr | ₹506.32 Cr | ₹589.11 Cr | ₹448.89 Cr |
| Cost of Materials Consumed | ₹159.19 Cr | ₹114.24 Cr | ₹203.53 Cr | ₹159.5 Cr | ₹156.87 Cr | ₹121.53 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹2.52 Cr | ₹13.71 Cr | -₹63.41 Cr | -₹18.39 Cr | ₹10.85 Cr | -₹70.1 Lakh |
| Employee Benefit Expense | ₹186.65 Cr | ₹172.99 Cr | ₹162.79 Cr | ₹160.62 Cr | ₹151.09 Cr | ₹132.94 Cr |
| Finance Costs | ₹7.83 Cr | ₹9.7 Cr | ₹9.35 Cr | ₹12.36 Cr | ₹10.89 Cr | ₹23.13 Cr |
| Depreciation & Amortisation | ₹45.31 Cr | ₹44.08 Cr | ₹39.75 Cr | ₹37.72 Cr | ₹37.49 Cr | ₹34.09 Cr |
| Other Expenses | ₹77.23 Cr | ₹67.67 Cr | ₹88.73 Cr | ₹73.76 Cr | ₹103.12 Cr | ₹66.26 Cr |
| Total Expenses | ₹478.72 Cr | ₹422.39 Cr | ₹440.74 Cr | ₹425.58 Cr | ₹470.31 Cr | ₹377.25 Cr |
| Profit Before Exceptional Items & Tax | ₹138.94 Cr | ₹142.46 Cr | ₹112.05 Cr | ₹80.75 Cr | ₹118.8 Cr | ₹71.65 Cr |
| Exceptional Items | ₹29.2 Lakh | -₹8.29 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹139.23 Cr | ₹134.17 Cr | ₹112.05 Cr | ₹80.75 Cr | ₹118.8 Cr | ₹71.65 Cr |
| Total Tax Expense | ₹34.99 Cr | ₹33.79 Cr | ₹28.21 Cr | ₹20.29 Cr | ₹30.53 Cr | ₹17.8 Cr |
| Net Profit | ₹104.24 Cr | ₹100.38 Cr | ₹83.84 Cr | ₹60.46 Cr | ₹88.27 Cr | ₹53.85 Cr |
| attributable to Owners | - | ₹0 | ₹0 | - | - | ₹0 |
| attributable to NCI | - | ₹0 | ₹0 | - | - | ₹0 |
| Other Comprehensive Income | -₹9.11 Cr | ₹91.1 Lakh | -₹14.23 Cr | ₹1.62 Cr | ₹7.34 Cr | -₹3.9 Cr |
| Total Comprehensive Income | ₹95.12 Cr | ₹101.29 Cr | ₹69.61 Cr | ₹62.07 Cr | ₹95.61 Cr | ₹49.96 Cr |
| EBITDA (computed) | ₹192.07 Cr | ₹196.23 Cr | ₹161.15 Cr | ₹130.84 Cr | ₹167.17 Cr | ₹128.87 Cr |
| Basic EPS | ₹4.93 | ₹4.77 | ₹4.01 | ₹2.90 | ₹4.24 | ₹2.89 |
| Diluted EPS | ₹4.87 | ₹4.71 | ₹3.93 | ₹2.83 | ₹4.14 | ₹2.84 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹2,153.23 Cr | ₹1,642.05 Cr |
| Other Income | ₹49.13 Cr | ₹37.34 Cr |
| Total Income | ₹2,202.36 Cr | ₹1,679.38 Cr |
| Cost of Materials Consumed | ₹568.34 Cr | ₹445.52 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 |
| Changes in Inventories | -₹7.76 Cr | ₹4.13 Cr |
| Employee Benefit Expense | ₹617.73 Cr | ₹485.56 Cr |
| Finance Costs | ₹32.62 Cr | ₹70.03 Cr |
| Depreciation & Amortisation | ₹152.3 Cr | ₹126.03 Cr |
| Other Expenses | ₹374.96 Cr | ₹316.4 Cr |
| Total Expenses | ₹1,738.18 Cr | ₹1,447.67 Cr |
| Profit Before Exceptional Items & Tax | ₹464.17 Cr | ₹231.72 Cr |
| Exceptional Items | -₹8 Cr | ₹0 |
| Profit Before Tax | ₹456.17 Cr | ₹231.72 Cr |
| Total Tax Expense | ₹114.69 Cr | ₹58.25 Cr |
| Net Profit | ₹341.48 Cr | ₹173.46 Cr |
| Other Comprehensive Income | -₹28.22 Cr | ₹91.5 Lakh |
| Total Comprehensive Income | ₹313.26 Cr | ₹174.38 Cr |
| EBITDA (computed) | ₹649.09 Cr | ₹427.78 Cr |
| Basic EPS | ₹16.27 | ₹9.00 |
| Diluted EPS | ₹16.08 | ₹8.78 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹3,602.82 Cr | ₹3,136.66 Cr |
| Non-current Assets | ₹2,203.69 Cr | ₹1,642.12 Cr |
| Current Assets | ₹1,399.13 Cr | ₹1,494.54 Cr |
| Property, Plant & Equipment | ₹1,698.61 Cr | ₹1,367.04 Cr |
| Inventories | ₹149.9 Cr | ₹118.33 Cr |
| Trade Receivables | ₹369.71 Cr | ₹352.87 Cr |
| Cash & Equivalents | ₹78.6 Cr | ₹85.19 Cr |
| Equity (Net Worth) | ₹2,507.97 Cr | ₹2,167.46 Cr |
| Equity Share Capital | ₹21.18 Cr | ₹20.84 Cr |
| Borrowings (Non-current) | ₹20.5 Cr | ₹0 |
| Borrowings (Current) | ₹74.62 Cr | ₹128.64 Cr |
| Total Debt (computed) | ₹95.13 Cr | ₹128.64 Cr |
| Current Liabilities | ₹842.26 Cr | ₹727.2 Cr |
| Total Liabilities | ₹1,094.85 Cr | ₹969.2 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹495.27 Cr | ₹330.35 Cr |
| Investing Cash Flow | -₹392.71 Cr | -₹564.71 Cr |
| Financing Cash Flow | -₹109.23 Cr | ₹314.31 Cr |
| Capital Expenditure | ₹590.26 Cr | ₹363.49 Cr |
| Free Cash Flow (computed) | -₹94.99 Cr | -₹33.14 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | -₹6.52 Cr | ₹79.95 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹594.34 Cr | ₹549.18 Cr | ₹526.67 Cr | ₹483.04 Cr | ₹567.01 Cr | ₹428.6 Cr |
| Other Income | ₹15.75 Cr | ₹8.45 Cr | ₹14.93 Cr | ₹10.01 Cr | ₹9.82 Cr | ₹9.45 Cr |
| Total Income | ₹610.09 Cr | ₹557.63 Cr | ₹541.6 Cr | ₹493.04 Cr | ₹576.83 Cr | ₹438.05 Cr |
| Cost of Materials Consumed | ₹158.48 Cr | ₹112.76 Cr | ₹141.78 Cr | ₹155.33 Cr | ₹154.06 Cr | ₹116.92 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹1.99 Cr | ₹13.78 Cr | -₹5.37 Cr | -₹18.15 Cr | ₹10.33 Cr | -₹25.5 Lakh |
| Employee Benefit Expense | ₹169.88 Cr | ₹159.23 Cr | ₹146.04 Cr | ₹142.59 Cr | ₹134.55 Cr | ₹121.06 Cr |
| Finance Costs | ₹6.16 Cr | ₹8.06 Cr | ₹7.7 Cr | ₹10.7 Cr | ₹9.16 Cr | ₹21.66 Cr |
| Depreciation & Amortisation | ₹41.16 Cr | ₹40.6 Cr | ₹36.21 Cr | ₹34.33 Cr | ₹34.1 Cr | ₹31.07 Cr |
| Other Expenses | ₹95.85 Cr | ₹84.45 Cr | ₹104.38 Cr | ₹90.27 Cr | ₹114.16 Cr | ₹79.69 Cr |
| Total Expenses | ₹473.53 Cr | ₹418.86 Cr | ₹430.73 Cr | ₹415.06 Cr | ₹456.36 Cr | ₹370.14 Cr |
| Profit Before Exceptional Items & Tax | ₹136.56 Cr | ₹138.76 Cr | ₹110.87 Cr | ₹77.98 Cr | ₹120.47 Cr | ₹67.91 Cr |
| Exceptional Items | ₹29.2 Lakh | -₹8.29 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹136.85 Cr | ₹130.47 Cr | ₹110.87 Cr | ₹77.98 Cr | ₹120.47 Cr | ₹67.91 Cr |
| Total Tax Expense | ₹34.32 Cr | ₹32.84 Cr | ₹27.92 Cr | ₹19.61 Cr | ₹30.53 Cr | ₹16.86 Cr |
| Net Profit | ₹102.53 Cr | ₹97.63 Cr | ₹82.95 Cr | ₹58.37 Cr | ₹89.94 Cr | ₹51.06 Cr |
| Other Comprehensive Income | -₹13.15 Cr | ₹8.8 Lakh | -₹16.65 Cr | ₹1.49 Cr | ₹7.31 Cr | -₹5.14 Cr |
| Total Comprehensive Income | ₹89.38 Cr | ₹97.72 Cr | ₹66.3 Cr | ₹59.86 Cr | ₹97.24 Cr | ₹45.92 Cr |
| EBITDA (computed) | ₹183.89 Cr | ₹187.42 Cr | ₹154.78 Cr | ₹123 Cr | ₹163.72 Cr | ₹120.64 Cr |
| Basic EPS | ₹4.85 | ₹4.64 | ₹3.97 | ₹2.80 | ₹4.32 | ₹2.74 |
| Diluted EPS | ₹4.79 | ₹4.58 | ₹3.89 | ₹2.73 | ₹4.22 | ₹2.69 |
Board & Governance of Sai Life Sciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Sai Life Sciences Limited has 6 directors - 3 independent and 3 executive. The board is chaired by Ranga Raju Kanumuri.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Ranga Raju Kanumuri | Executive Director · Chairperson | 1999-01-25 | 1 |
| Kanumuri Krishnam Raju | Executive Director | 2010-10-01 | 1 |
| Ramesh Ganesh Iyer | Non-Executive - Independent Director | 2024-05-21 | 3 |
| Dinesh V Patel | Non-Executive - Independent Director | 2025-03-24 | 1 |
| Suchita Sharma | Non-Executive - Independent Director | 2024-06-10 | 1 |
| Sivaramakrishnan Chittor | Executive Director | 2025-04-28 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Suchita Sharma (Chairperson), Dinesh V Patel, Ramesh Ganesh Iyer |
| Nomination and remuneration committee | Ramesh Ganesh Iyer (Chairperson), Dinesh V Patel, Suchita Sharma |
| Stakeholders Relationship Committee | Ramesh Ganesh Iyer (Chairperson), Kanumuri Krishnam Raju, Suchita Sharma |
| Risk Management Committee | Ramesh Ganesh Iyer (Chairperson), Kanumuri Krishnam Raju, Sivaramakrishnan Chittor |
| Corporate Social Responsibility Committee | Suchita Sharma (Chairperson), Ramesh Ganesh Iyer, Kanumuri Krishnam Raju, Dinesh V Patel, Sivaramakrishnan Chittor |
Charges & Borrowings of Sai Life Sciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹100 Cr | Open |
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹18.76 Cr | Open |
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹25 Cr | Open |
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹768.6 Cr | Open |
| 06 Oct 2023 | Sbicap Trustee Company Limited | ₹75 Cr | Satisfied |
Total charge records: 37 View all charges
Employees and EPFO Compliance at Sai Life Sciences Limited
View historical data on people associated with Sai Life Sciences Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Sai Life Sciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Sai Life Sciences Limited
GSTIN & GST Filing Data of Sai Life Sciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Sai Life Sciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Sai Life Sciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Sai Life Sciences Limited
MSME Payment Delays by Sai Life Sciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Sai Life Sciences Limited
Subsidiaries & Group Companies of Sai Life Sciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sai Life Sciences Limited with ownership details.
MCA Filings & Documents of Sai Life Sciences Limited
MCA Filings & Documents of Sai Life Sciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Sai Life Sciences Limited
Recent News on Sai Life Sciences Limited
Frequently Asked Questions about Sai Life Sciences Limited
Sai Life Sciences Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 25 January 1999 (27+ years old) and is registered under CIN L24110TG1999PLC030970. The company has 2,995 employees.
Sai Life Sciences Limited reported revenue of ₹1,731.35 Cr for FY 2025 (up 16.00% YoY).
The current directors of Sai Life Sciences Limited are:
The primary industry of Sai Life Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes, Sai Life Sciences Limited is a listed company.
Sai Life Sciences Limited can be reached at the registered office: Plot No. Ds – 7 Ikp Knowledge Park Turkapally V Shameerpet Mandal Medchal – Malkajgiri Di, St, Hyderabad, Telangana, India – 500078, or through the website sailife.com.